...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.
【24h】

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.

机译：在患有复发且可测量疾病的惰性B细胞淋巴瘤患者中，用自体肿瘤加载的树突状细胞接种疫苗可诱导临床和免疫应答：一项先导研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Eighteen relapsed patients with measurable indolent non-Hodgkin lymphoma (NHL) were vaccinated with dendritic cells (DCs) loaded with killed autologous tumor cells. Six patients had objective clinical responses including 3 continuous complete responses (CRs) and 3 partial responses (PRs), with a median follow up of 50.5 months. Eight patients had stable disease, whereas 4 had progressive disease. Clinical responses were significantly associated with a reduction in CD4(+)CD25(+)FOXP3(+) regulatory T cells, an increase in CD3(-)CD56(dim)CD16(+) natural killer (NK) cells, and maturation of lymphocytes to the effector memory stage in either postvaccination peripheral blood or tumor specimen samples. In partial responding patients, vaccination significantly boosted the IFN-gamma-producing T-cell response to autologous tumor challenge. In one HLA-A*0201(+) patient who achieved CR, IL-4 release by circulating T cells in response to tumor-specific IgH-encoded peptides was also documented. Immunohistochemical analysis of tumor biopsies using biotin-conjugated autologous serum samples revealed a tumor-restricted humoral response only in the postvaccination serum from responding patients. Collectively these results demonstrate that vaccination with tumor-loaded DCs may induce both T- and B-cell responses and produces clinical benefits in indolent NHL patients with measurable disease. This study is registered with the Istituto Superiore di Sanita: http://www.iss.it with protocol number 7578-PRE 21-801.
机译：对18例可测量的惰性非霍奇金淋巴瘤（NHL）复发患者进行接种树突状细胞（DC）的接种，这些树突状细胞负载已杀死的自体肿瘤细胞。 6例患者有客观的临床反应，包括3例连续完全缓解（CR）和3例部分缓解（PR），中位随访时间为50.5个月。 8名患者病情稳定，而4名患者进行性疾病。临床反应与CD4（+）CD25（+）FOXP3（+）调节性T细胞减少，CD3（-）CD56（dim）CD16（+）自然杀伤（NK）细胞增加以及免疫后外周血或肿瘤标本样本中的淋巴细胞达到效应记忆阶段。在部分反应患者中，疫苗接种显着增强了产生IFN-γ的T细胞对自体肿瘤激发的反应。在一名获得CR的HLA-A * 0201（+）患者中，也记录了通过循环T细胞响应肿瘤特异性IgH编码肽释放IL-4。使用结合了生物素的自体血清样本对肿瘤活检进行的免疫组织化学分析显示，仅在应答患者的疫苗接种后血清中，肿瘤限制了体液应答。这些结果共同表明，在肿瘤可测量的惰性NHL患者中，接种肿瘤的DC疫苗可诱导T细胞和B细胞反应，并产生临床益处。该研究已在Sanita的Istituto Superiore di Sanita中进行了注册：http：//www.iss.it，协议编号7578-PRE 21-801。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号